Key Takeaways
- Exceptional U.S. quarter, guidance raised: U.S. Generics revenue surged 72% YoY, powered by the bosutinib exclusivity and mid-20s base volume growth, prompting management to lift FY27 consolidated growth guidance to 20–25%.
- India branded business turns the corner: India Human Health returned to 11% YoY double-digit growth, with chronic and specialty therapies outpacing the IPM; management expects to hit market-level growth within 2–3 quarters.
- Complex generics pipeline deepens via DifGen: A new strategic collaboration adds >20 differentiated products (patches, complex injectables, ophthalmics) with FTF and day-1 opportunities, a capital-efficient path to sustaining U.S. momentum beyond bosutinib.
- Margins expand sharply, investment phase intact: EBITDA margin jumped ~520 bps YoY to 22.2% on operating leverage and disciplined R&D spend, while the company absorbed planned U.S. branded dilution and freight cost inflation.
- What to watch next quarter: The pace of India acute recovery toward IPM, post-exclusivity bosutinib market dynamics from December, and any quantitative signal on U.S. branded ramp-up trajectory.
U.S. Generics: The Bosutinib Quarter and Beyond
- Bosutinib windfall: The product performed far above expectations and exclusivity runs through end-November, so October and November contributions are still to come; management offered no forecast for the post-exclusivity market.
- Base business strength is independent: Even excluding bosutinib, the base portfolio grew 23% in Q2, confirming the core is driven by volume growth, not one-off exclusivity gains.
- Launch cadence provides visibility: A steady pipeline of >30 launches over the next 18 months, roughly 25% of which are FTF or shared day-1 opportunities, supports growth beyond the current exclusivity period.
- FY28 early look: If all launches pan out, U.S. growth could settle close to mid, about 10–12%, a normalization from the FY27 spike but still healthy.
- DifGen collaboration fills complex-generics gap: The basket deal covers transdermal patches, complex injectables, and dosage forms Alembic lacks, with profit sharing and U.S. manufacturing access; contributions begin FY28 and scale over subsequent years.
Pranav Amin: "So bosutinib has done, yes, far higher than expectations or what we expect. It's -- as you know, we have exclusivity till end of November. So we've got 2 more months, which will be October, November, we'll see. What happens after that, I don't know. Let's see what the market shapes up as."
India Branded: The Turnaround Thesis
- Chronic and specialty lead the recovery: Gynecology, cardiology, and emerging therapies drove growth, with the specialty portfolio growing ~200 bps ahead of IPM; chronic outpaced the market while acute still lags.
- Acute drag is acknowledged and time-bound: Management expects the acute segment to reach IPM-level growth within the next couple of quarters, which would close the overall gap.
- Volume and price split evenly: Directionally, India growth is almost 50-50 between price and volume, though management declined to disclose the precise breakdown.
- Metro weakness is a known gap: Geographic coverage in metros remains quite weak and is an explicit area for improvement over the next couple of quarters.
- Margin tailwind is contingent on growth: The first priority is reaching IPM-level growth; once achieved with a steady growth rate and no field force expansion, higher PCPM and gradual margin improvement should follow automatically.
Pranav Amin: "So over the next couple of quarters, we should be at IPM or higher."
U.S. Branded: Early Innings, Defined Cost
- Commercial traction is building month-on-month: Prescriptions, formulary access, and physician response are progressing in line with plan for NUVESSA, NUVETEST, and the newly launched Pivya, which is on a J-shaped adoption curve.
- Field force nearing target: The branded sales force stands at 30–35 reps, progressing toward a goal of 40–45, and all Medicaid and insurance company coverages are secured.
- Dilution is quantified and finite: The 150–200 bps EBITDA dilution guidance for the full year still holds, and management expects the branded business to reach breakeven by end-FY27 or first half FY28, implying no drag in FY28.
- Guidance withheld deliberately: Management has an internal target for branded contribution but declined to share it, preferring to wait until year-end when the next half provides more confidence on the ramp-up trajectory.
Pranav Amin: "I believe that we will start breaking even in the first half of next -- by the end of this year or the first half of next year is when we'll break even. But the trends are positive. I think we're seeing a month-on-month increase in the activities and prescriptions as well."
Margins: Expansion with Embedded Investment
- Gross margin held within guided range: At 73.7%, up 70 bps YoY, the gross margin absorbed higher solvent costs, freight inflation, and geopolitical headwinds, benefiting from favorable product mix.
- EBITDA margin jump was broad-based: The ~520 bps YoY expansion to 22.2% reflected operating leverage from ramped-up facility utilization, disciplined R&D spend growth, and new launch contribution, while absorbing planned U.S. branded investment.
- Cost increases are structural but manageable: Employee costs rose on annual increments and U.S. branded field force hiring; other expenses climbed on promotion/marketing and freight costs that have been elevated since March.
- H2 margin profile expected to hold: With H1 at ~22% EBITDA, management expects the margin profile to continue through the second half, implying full-year margins near current levels.
- Medium-term ambition: Management would like to move toward 20%-type EBITDA margins in FY28 and FY29, with levers including operating leverage from existing facilities and the dilution unwind as U.S. branded reaches breakeven.
G. Krishnan: "So I think you should look at the interplay how the gross margin to EBITDA is flowing through what we expect for the full year -- for the first half, we have about 22% EBITDA margins, which we expect to continue towards the second half as well. So we should expect the margin profile to hold for the rest of the year."
Capital Allocation and Returns
- Major capex cycle is behind: H1 FY27 capex was ₹250 crores; the focus now is on debottlenecking and incremental line additions without significant new greenfield investment, which management expects will improve asset turns and returns.
- Net debt is comfortable: At ₹1,236 crores, net debt is less than 1x full-year EBITDA; working capital is temporarily stretched by longer collection cycles on new U.S. launches, expected to unwind progressively over the next few quarters.
- Tax rate normalizes, cash tax stays low: The effective tax rate moved to 25% in FY27, but cash tax continues at ~18.75% given available MAT credit.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | 20% to 25% YoY (raised from mid-teens) | FY27 |
| U.S. business growth | Up to 40% YoY | FY27 |
| API business growth | At least high teens YoY | FY27 |
| India branded growth | Align with market, reach IPM or higher | Next 2–3 quarters |
| Acute segment recovery | Reach IPM-level growth | Next couple of quarters |
| Ex-U.S. markets growth | Mid-teens | FY27 |
| EBITDA margin | ~22% profile to hold | H2 FY27 |
| Gross margin | Remain within 70–75% range | Ongoing |
| U.S. branded EBITDA dilution | 150–200 bps | FY27 |
| U.S. branded breakeven | Breakeven achieved | End-FY27 to H1 FY28 |
| U.S. generics launches | >30 launches, ~25% FTF/day-1 | Next 18 months |
| DifGen collaboration contribution | Revenue contribution begins | FY28 |
| U.S. growth (normalized) | Close to mid, about 10–12% | FY28 (if launches pan out) |
| Medium-term EBITDA margin | Move toward 20% | FY28–FY29 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹2,603 crores, +36% YoY |
| India business growth | 14% YoY |
| Human Health growth | 11% YoY |
| Animal Health growth | 23% YoY |
| U.S. Generics revenue growth | 72% YoY |
| U.S. Generics base portfolio growth (ex-new launches) | 23% YoY |
| Ex-U.S. markets growth | 12% YoY |
| API business growth | 39% YoY, volume-led including certain CMO deliveries |
| Gross margin | 73.7%, expanded 70 bps YoY |
| R&D expenditure | 8% of revenue |
| EBITDA margin | 22.2%, expanded ~520 bps YoY from 17% in Q2 last year |
| Profit after tax | ₹335 crores, +81% YoY |
| Effective tax rate | ~24%, compared with 18% in previous year |
| Net debt | ₹1,236 crores, less than 1x full year EBITDA |
| H1 FY27 capex | ~₹250 crores |
| FY27 consolidated revenue growth guidance (raised) | About 20% to 25%, up from mid-teens indicated last quarter |
| FY27 U.S. business growth guidance (raised) | Up to 40% YoY for full year |
| FY27 API business growth guidance (raised) | At least high teens for full year |
| U.S. branded contribution to total U.S. revenue | Close to 3% |
| U.S. branded business full-year EBITDA dilution guidance | 150 to 200 bps |
| U.S. pipeline launches over next 18 months | More than 30, with around a quarter being FTF or shared day-1 opportunities |
| DifGen collaboration portfolio size | Over 20 products, addressing aggregate U.S. reference market of ~$5 billion |
| U.S. branded field force | 30 to 35 reps currently, goal of 40 to 45 |
| U.S. branded breakeven expectation | By end of FY27 or first half of FY28 |
| FY28 U.S. growth expectation | About 10% to 12% if all launches pan out well |